newsfilter
← Latest News
ACCESS Newswire·

Novamind Participates in Alto Neuroscience Phase II Clinical Trial for MDD and PTSD

Clinical trial underway at Novamind's Draper, UT research site TORONTO, ON / ACCESSWIRE / February 9, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine,